Symbiotec Pharmalab Limited (NSE:SYMBIOTEC)

India · Delayed Price · Currency is INR

1,198.00

+21.25 (1.81%)

At close: Oct 1, 2026

Market Cap	76.98B
Revenue (ttm)	8.84B +23.4%
Net Income	940.20M -6.1%
EPS	14.98 -16.7%
Shares Out	64.26M
PE Ratio	79.95
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,713,662
Open	1,194.00
Previous Close	1,176.75
Day's Range	1,161.10 - 1,246.00
52-Week Range	934.20 - 1,246.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 21, 2026

About Symbiotec Pharmalab

Symbiotec Pharma Lab Pvt. Ltd. develops, manufactures, and markets active pharmaceutical ingredients (APIs), with a primary focus on cortico-steroids and steroid-hormone APIs in both sterile and non-sterile forms. The company synthesizes progestin, estrone, testosterone, their derivatives, and anabolic steroids, supplying these in commercial volumes globally. It offers APIs and intermediate pharmaceutical products for therapeutic areas such as gastrointestinal ailments, cardiovascular disease, pain management, paediatrics, anti-infective, and d... [Read more]

Industry Medicinal Chemicals and Botanical Products

Founded 1995

Employees 1,915

Stock Exchange National Stock Exchange of India

Ticker Symbol SYMBIOTEC

Full Company Profile

Financial Performance

In fiscal year 2026, Symbiotec Pharmalab's revenue was 8.69 billion, an increase of 15.65% compared to the previous year's 7.52 billion. Earnings were 1.10 billion, an increase of 13.53%.

Financial Statements